Effective Phaco Time and Endothelial Cell Loss When Using Veritas
Assessment of Effective Phaco Time and Endothelial Cell Loss When Using a Novel Dual Mode Phacoemulsification System
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Adult patients undergoing age-related cataract surgery. * Planned use of the Catalys Precision Laser System. * Planned implantation of TECNIS intraocular lenses (IOLs). Exclusion Criteria: • Moderate-severe any disease state (deemed by the surgeon) that could increase risk of complicated cataract surgery (ie, pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma, and prior refractive surgery).
About the study
This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.
What is being tested
- Veritas Vision System (device)
Sponsor: Aloha Vision Consultants · Participants: 50 · Started: Oct 3, 2025
Contact the study team
- Alana K Dunn · Phone: 808-688-6898
Official record on ClinicalTrials.gov — NCT07176416
Locations in the U.S.
| Hawaii | Aloha Vision Consultants, ‘Aiea |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.